Related Experiment Video
Updated: Oct 9, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Microtubule-Interfering Drugs: Current and Future Roles in Epithelial Ovarian Cancer Treatment
Joan Tymon-Rosario1, Naomi N Adjei1, Dana M Roque2
1Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University School of Medicine, New Haven, CT 06520, USA.
Abstract:
Taxanes and epothilones are chemotherapeutic agents that ultimately lead to cell death through inhibition of normal microtubular function. This review summarizes the literature demonstrating their current use and potential promise as therapeutic agents in the treatment of epithelial ovarian cancer (EOC), as well as putative mechanisms of resistance. Historically, taxanes have become the standard of care in the front-line and recurrent treatment of epithelial ovarian cancer. In the past few years, epothilones (i.e., ixabepilone) have become of interest as they may retain activity in taxane-treated patients since they harbor several features that may overcome mechanisms of taxane resistance. Clinical data now support the use of ixabepilone in the treatment of platinum-resistant or refractory ovarian cancer. Clinical data strongly support the use of microtubule-interfering drugs alone or in combination in the treatment of epithelial ovarian cancer. Ongoing clinical trials will shed further light into the potential of making these drugs part of current standard practice.
Insights
Taxanes and epothilones are microtubule-targeting chemotherapies for epithelial ovarian cancer (EOC). Epothilones show promise in treating platinum-resistant EOC, potentially overcoming taxane resistance.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Taxanes and epothilones are microtubule-targeting chemotherapeutic agents.
- They induce cell death by inhibiting microtubule function.
- Epithelial ovarian cancer (EOC) treatment relies heavily on these agents.
Purpose of the Study:
- To review the current use and potential of taxanes and epothilones in treating EOC.
- To explore mechanisms of resistance to these therapies.
- To highlight the role of epothilones in overcoming taxane resistance.
Main Methods:
- Literature review of clinical data and research on taxanes and epothilones in EOC.
- Analysis of mechanisms of drug resistance.
- Evaluation of ixabepilone's efficacy in platinum-resistant or refractory EOC.
Main Results:
- Taxanes are the standard of care for front-line and recurrent EOC.
- Epothilones, like ixabepilone, demonstrate activity in taxane-resistant EOC.
- Ixabepilone is supported by clinical data for platinum-resistant or refractory EOC.
Conclusions:
- Microtubule-interfering drugs are crucial in EOC treatment, alone or in combination.
- Epothilones offer a potential therapeutic option for patients resistant to taxanes.
- Ongoing trials will further define the role of these agents in standard EOC therapy.
More Related Videos
Related Concept Videos
Drugs that Stabilize Microtubules
Drugs that Destabilize Microtubules
Destabilization of Microtubules
Targeted Cancer Therapies
There are several types of targeted therapies against...
Inhibition of Cdk Activity
Microtubule Instability

